Register for free to listen to this article
Listen with Speechify
0:00
2:00
It's a crowded market for trade publications covering drug discovery. We know that. We also know that in order to stand out in a crowd you need to be different. With that, we introduce you to Drug Discovery News a trade publication that's more like the business section of your daily newspaper, than any other publication covering drug discovery. This is no "me too" publication that is feature rich, technology-focused and light on news.
 
We are a newspaper. Printed on newsprint. Sized like a newspaper. Designed like a newspaper. Most importantly, we report stories like a newspaper. This means our reporting of the news doesn't begin and end with the company news release. For Drug Discovery News, the press releases that pique our interest are merely the starting point. From there our business news journalists hit the phones and conduct interviews with the principals involved in a story and often those not directly involved to give an outside perspective. In other words, we dig to get the story behind the story and always with a keen eye toward how the story affects the business of drug discovery.
 
Every issue of Drug Discovery News will have a minimum of five bylined stories in each of the four major sections of the newspaper: informatics, genomics & proteomics, automation & instrumentation and research & development. That's a total of 20 bylined stories each and every month in the major sectors of industry, the sectors that affect how your business operates, how companies come to market, how they compete and where the emerging opportunities lie.
 
But let's be honest, the best concept will not work unless you have the personnel to execute the plan. Well, this premier issue of Drug Discovery News isn't short on editorial experience either. The editors whose work appears in these pages have a combined total of more than 30 years business journalism and trade publishing experience.
 
To wit:
Chris Anderson has more than 15 years of business journalism and editorial experience. He led the editorial start-up of Security Systems News as its first editor and has also worked on the start-up of two other newspapers, HME News for the home medical equipment industry and the alternative newspaper Casco Bay Weekly in Portland, Maine. Anderson's business journalism spans industries as diverse as semiconductors, custom home electronics and gourmet and specialty foods.
 
Randall C Willis should be familiar to most of our readers. He is a former editor of the American Chemical Society's Modern Drug Discovery and Journal of Proteome Research. He is also a one-time publisher of his own science magazine. Willis has been writing about and discussing scientific R&D for more than 15 years and brings an in-depth knowledge of drug discovery to these pages.
 
Jeffrey Bouley is a writer and editor with more than 15 years of experience as a freelancer and as managing editor, senior editor and staff editor at a variety of professional and trade magazines.
A graduate of Northwestern University, where he earned bachelor's and master's degrees in journalism, Jeff has spent most of his career covering health, medical and environmental issues.
 
In short, we have the tools, the knowledge and the wherewithal to provide you with the vital news — business intelligence, if you will —that will make you a more competent player in the market.
So read on and let us know what you think. We think you'll like what you see.

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A person wearing a white lab coat types on a laptop with various overlaid enlarged files shown with plus signs on file folders floating over the laptop screen with a clinical lab shown in the background in grey and white tones.

Enhancing bioanalytical studies with centralized data management

Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
A 3D-rendered digital illustration of a molecular structure floating among red blood cells in a bloodstream environment.

Explained: How are metabolite biomarkers improving drug discovery and development?

By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.
Clear cells with round, blue centers are shown against a varied blue background

Supercharging cell line development and engineering with automated single cell sorting

Researchers can enhance efficiency, yield, and consistency in clonal cell line development with specialized tools.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue